FR0010259150

Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance

H1 total sales growth of 11.4% at CER1, or 9.7% as reported, driven by the three therapeutic areas: 95.7% in…

10 months ago

IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2025

Aggregated presentation by day and by market Statement of transactions in own shares from June 2nd to June 6th 2025       Name…

11 months ago